Education
About Us
Working with TipRanks
Follow Us
VolitionRX (VNRX)
:VNRX
VNRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.40 - $0.94
Previous CloseN/A
Volume29.92K
Average Volume (3M)165.30K
Market Cap
$66.55M
Enterprise Value$59.01M
Total Cash (Recent Filing)$2.60M
Total Debt (Recent Filing)$7.37M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Aug 13, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding103,982,020
10 Day Avg. Volume139,947
30 Day Avg. Volume165,299
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue45.11
Enterprise Value/Gross Profit45.11
Enterprise Value/Ebitda-2.61
Forecast
1Y Price Target
$2.75Price Target Upside343.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Licensing OpportunitiesLicensing deals are a top priority, with the company engaged in discussions with over 10 global diagnostic and pharmaceutical companies, presenting significant financial opportunities.
PartnershipsThe anticipated announcement of a partnership in the human health space is seen as the most important catalyst, promising potential non-dilutive capital and validation of the company's business strategy.
Product DevelopmentVolitionRx announced that it has demonstrated quantification of nucleosomes in whole venous blood in minutes using a lateral flow device, showcasing the feasibility of early detection of immune disruptions.
Bears Say
Clinical Development RisksRisks include failure in clinical development of diagnostic products, which could significantly impact the company's financial prospects.
Licensing Agreement RisksFailure to secure license agreements for diagnostic products is a risk that could hinder the company's licensing strategy and financial gains.
Market TractionFailure to achieve market traction with diagnostic products poses a risk to the company's growth and revenue potential.
VolitionRX News
VNRX FAQ
What was VolitionRX’s price range in the past 12 months?
VolitionRX lowest stock price was $0.40 and its highest was $0.94 in the past 12 months.
What is VolitionRX’s market cap?
VolitionRX’s market cap is $66.55M.
When is VolitionRX’s upcoming earnings report date?
VolitionRX’s upcoming earnings report date is Aug 13, 2025 which is in 7 days.
How were VolitionRX’s earnings last quarter?
VolitionRX released its earnings results on May 15, 2025. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.06.
Is VolitionRX overvalued?
According to Wall Street analysts VolitionRX’s price is currently Undervalued.
Does VolitionRX pay dividends?
VolitionRX does not currently pay dividends.
What is VolitionRX’s EPS estimate?
VolitionRX’s EPS estimate is -0.05.
How many shares outstanding does VolitionRX have?
VolitionRX has 103,982,020 shares outstanding.
What happened to VolitionRX’s price movement after its last earnings report?
VolitionRX reported an EPS of -$0.06 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.444%.
Which hedge fund is a major shareholder of VolitionRX?
Currently, no hedge funds are holding shares in VNRX
VolitionRX Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.75 (343.55% Upside)
$2.75 (343.55% Upside)
Blogger Sentiment
Bullish
VNRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $48.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 26.9%
Last 30 Days ▲ 43.5%
Last 30 Days ▲ 43.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.46%
12-Months-Change
Fundamentals
Return on Equity
138.92%
Trailing 12-Months
Asset Growth
-56.16%
Trailing 12-Months
Company Description
VolitionRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
VNRX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented several positive developments, including significant revenue growth, reduced operating expenses, and progress in licensing and commercialization efforts across various segments. However, challenges such as a decline in cash position and uncertainties in revenue predictions were noted. Overall, the positive highlights outweigh the lowlights, indicating a promising outlook for the company.Read More>VNRX Stock 12 Month Forecast
Average Price Target
$2.75
▲(343.55%Upside)
Technical Analysis
Enzo Biochem
―
BioNano Genomics
―
Burning Rock Biotech
―
Biodesix
―
bioAffinity Technologies, Inc.
―
Ownership Overview
11.88% Insiders
1.28% Mutual Funds
0.19% Other Institutional Investors
85.83% Public Companies and
Individual Investors